checkAd
    Startseite > Aktien > Lantern Pharma > Nachrichten
    Lantern Pharma Aktie
    6,2700
     
    USD
    +0,64 %
    +0,0400 USD
    Letzter Kurs 25.05.24 Nasdaq
    6,2300
     
    USD
    300 STK
    Geldkurs 24.05.24
    6,3200
     
    USD
    200 STK
    Briefkurs 24.05.24
    ISIN: US51654W1018 · WKN: A2P5NM · SYM: LTRN · USA

    Neueste Nachrichten

    Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
    09.05.24 · Business Wire (engl.) · Lantern Pharma
    Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
    06.05.24 · Business Wire (engl.) · Lantern Pharma
    Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4: 30 p.m. ET
    02.05.24 · Business Wire (engl.) · Lantern Pharma
    Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
    24.04.24 · Business Wire (engl.) · Lantern Pharma
    Lantern Pharma Receives Regulatory Approval to Expand Harmonic Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
    22.04.24 · Business Wire (engl.) · Lantern Pharma
    Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
    18.03.24 · Business Wire (engl.) · Lantern Pharma
    Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
    15.03.24 · Business Wire (engl.) · Lantern Pharma
    Lantern Pharma to Report Fourth Quarter and Fiscal Year 2023 Operating & Financial Results on March 18th, 2024 at 4: 30 p.m. ET
    11.03.24 · Business Wire (engl.) · Lantern Pharma
    Lantern To Participate in H.C Wainwright & Co.’s (HCW) 1st Annual Artificial Intelligence Based Drug Discovery & Development Virtual Conference
    05.03.24 · Business Wire (engl.) · Lantern Pharma
    Lantern Pharma's A.I. Platform, RADR, Surpasses 60 Billion Data Points – Anticipates Reaching 100 Billion Data Points in 2024, Paving the Way for Enhanced Cancer Therapy Innovations and Expedited Development Timelines
    04.03.24 · Business Wire (engl.) · Lantern Pharma
    Lantern Pharma Advances Unique ADC (Antibody Drug Conjugate) Program Across Multiple Solid Tumor Cancers
    15.02.24 · Business Wire (engl.) · Lantern Pharma
    Starlight Therapeutics, a Subsidiary of Lantern Pharma Focused on CNS & Brain Cancers, Announces Dr. Marc Chamberlain as Chief Medical Officer
    17.01.24 · Business Wire (engl.) · Lantern Pharma